UK-based GW Pharmaceuticals nets $29mm in US IPO
Executive Summary
GW Pharmaceuticals PLC, UK developer of prescription cannabinoids, netted $29mm in its initial public offering in the US on the Nasdaq. As planned, it sold 3.5mm ADSs for $8.90. The company has been trading publicly on the London Stock Exchange’s AIM since June 2001.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice